600161.SS
600161.SS
CNE000000WF9
BEIJING TIANTAN BIOLOGICAL PROD
Loading chart...

Company Profile

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.

Related stocks

002007.SZ
002007.SZ • China
HUALAN BIO.
13.35 CNY
3.65B USD 1Y -17.6%
002252.SZ
002252.SZ • China
SHANGHAI RAAS
5.06 CNY
4.99B USD 1Y -25.4%
2315.HK
2315.HK • China
BIOCYTOGEN-B
69.2 HKD
3.91B USD 1Y +170.7%
300255.SZ
300255.SZ • China
CHANGSHAN PHARMA
22.15 CNY
3.05B USD 1Y -55.1%
688336.SS
688336.SS • China
SUNSHINE GUOJIAN PHARMACEUTICAL
38.1 CNY
5.11B USD 1Y +4.2%
1530.HK
1530.HK • China
3SBIO
15.07 HKD
4.76B USD 1Y -47.3%
9969.HK
9969.HK • China
INNOCARE
12.73 HKD
2.87B USD 1Y -23.4%
2696.HK
2696.HK • China
HENLIUS
50.75 HKD
3.53B USD 1Y -33%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
29.0% p.a.
Max Drawdown (5Y)
-57.4%
Sharpe Ratio (5Y)
-0.45
Beta Factor
0.22
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (29.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -67.8% in the extended horizon.
ende